Silencing MSH3 expression enhances cisplatin sensitivity of human tongue cancer cells.
- Author:
Xiao-Sheng FAN
1
;
Fang-Yun CAO
;
Kuang-Zheng LI
Author Information
- Publication Type:Journal Article
- MeSH: Apoptosis; Cell Line, Tumor; Cisplatin; pharmacology; DNA-Binding Proteins; genetics; metabolism; Gene Silencing; Humans; MutS Homolog 3 Protein; RNA, Small Interfering; Real-Time Polymerase Chain Reaction; Tongue Neoplasms; drug therapy; genetics; Transfection
- From: Journal of Southern Medical University 2016;36(8):1080-1084
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the effect of MSH3 knock-down on sensitivity of tongue cancer cells to cisplatin.
METHODSThree small interfering RNA (siRNA) fragments targeting MSH3 CDS region were synthesized and transfected into CAL27 cells via Lipofectamine. Real-time PCR and Western blotting were used to assess the efficiency of MSH3 silencing. MTS, apoptosis staining and cell immunofluorescence assay were used to examine the cisplatin sensitivity, apoptosis and DNA repair of transfected CAL27 cells.
RESULTSs One of the 3 siRNAs was found to significantly reduce the expression of MSH3 protein in CAL27 cells (P<0.05). MTS assay showed that MSH3 silencing resulted in an significant reduction of IC50 of cisplatin from 21.32 to 13.95 µmol/L (P<0.05) and increased the apoptotic index of the exposed cells from 4.23∓1.27 to 11.32∓1.82 (P<0.05). Immunofluorescence assay demonstrated that silencing MSH3 markedly reduced the number of γ-H2AX foci.
CONCLUSIONSilencing MSH3 can significantly increase cisplatin sensitivity of tongue cancer cells, the mechanism of which involves mainly attenuation of repair of DNA double-strand damage in the cells.
